47.97
+3.27%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AnaptysBio
From its filings with the US Securities and Exchange Commission
AnaptysBio is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ANAB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $234.6m and a net loss of $13.2m. At that date it held total assets of $364.4m and shareholders' equity of $37.2m.
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial. We also discovered and out-licensed, in financial collaborations, multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly) or “Jemperli”) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc. (“Vanda”). We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.
In September 2025, we announced that our board of directors (“Board of Directors”) approved plans to explore separating our business into two independent, publicly traded companies. One company is expected to hold and continue to manage the financial collaboration for Jemperli from GSK and for imsidolimab from Vanda, with a focus on protecting and returning value of the royalties to its shareholders.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jan 2017
- Employees
- 104
- Website
- anaptysbio.com ↗
- Head office
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. John OrwinNon-Executive Independent Chairman of the Board$456,694
- Mr. Daniel FagaPresident, Chief Executive Officer, Director, since 2021$13.6m
- Mr. Dennis MulroyChief Financial Officer$3.2m
- Dr. Paul LizzulChief Medical Officer$4.6m
- Mr. Eric LoumeauChief Legal Officer$2.3m
- Dr. Dennis FentonIndependent Director$441,694
- Dr. Rita JainIndependent Director$423,444
- Dr. Magda MarquetIndependent Director$426,694
- Mr. Oleg NodelmanIndependent Director
- Mr. Hollings RentonIndependent Director$426,694
- Mr. John SchmidIndependent Director$443,444
- Dr. J. Anthony WareIndependent Director$446,694
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 60
- Social
- 64
- Governance
- 44
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AnaptysBio Inc possesses several strengths that contribute to its success in the biotechnology industry. Firstly, the company has a strong and experienced management team with expertise in drug discovery and development. This enables them to make informed decisions and effectively navigate the complex regulatory landscape.
- Secondly, AnaptysBio Inc boasts a robust portfolio of proprietary antibody therapeutics, which have shown promising results in preclinical and clinical trials. These innovative products have the potential to address unmet medical needs and generate significant revenue for the company.
- Additionally, the company's strong financial position and access to capital provide them with the resources to further advance their research and development activities, and forge strategic partnerships with other industry leaders. This financial stability enables AnaptysBio Inc to pursue long-term growth and remain at the forefront of scientific advancements.
Weaknesses
- Despite its strengths, AnaptysBio Inc also faces certain weaknesses that may hinder its performance. One notable weakness is its dependence on a limited number of proprietary antibody programs. This concentration of resources increases the company's vulnerability to setbacks, such as failed clinical trials or patent disputes.
- Additionally, AnaptysBio Inc operates in a highly competitive industry, competing against larger pharmaceutical companies with substantial resources and established market presence. This competitive landscape puts pressure on the company to differentiate itself and successfully commercialize its products.
Opportunities
- AnaptysBio Inc has several opportunities to capitalize on in the biotechnology sector. One major opportunity lies in the increasing demand for innovative antibody-based therapies. The growing prevalence of chronic diseases and the need for personalized medicine create a favorable market environment for AnaptysBio Inc to introduce and market their products.
- Furthermore, the company can explore collaborations and licensing agreements with larger pharmaceutical companies to gain access to their established distribution networks and accelerate the commercialization of their products. This strategic approach can help penetrate new markets and broaden their revenue streams.
Threats
- AnaptysBio Inc faces various threats that could impact its future prospects. One significant threat is the risk of regulatory hurdles and delays in obtaining necessary approvals for their drug candidates. The stringent regulatory requirements in the biopharmaceutical industry can prolong the time to market and increase costs.
- Moreover, intellectual property disputes and patent challenges pose a threat to AnaptysBio Inc's market exclusivity and competitive advantage. Rival companies may challenge their patents, leading to lengthy legal battles that drain resources and potentially limit their market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.